Talis Biomedical (TLIS) Competitors

Bionano Genomics (NASDAQ:BNGO) and Talis Biomedical (NASDAQ:TLIS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

Which has better earnings and valuation, BNGO or TLIS?

Talis Biomedical has lower revenue, but higher earnings than Bionano Genomics. Talis Biomedical is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bionano Genomics	$30.78M	0.33	-$112.02M	-$138.92	-0.02
Talis Biomedical	$300K	9.12	-$62.01M	-$28.02	-0.05

Does the media refer more to BNGO or TLIS?

In the previous week, Bionano Genomics had 9 more articles in the media than Talis Biomedical. MarketBeat recorded 9 mentions for Bionano Genomics and 0 mentions for Talis Biomedical. Bionano Genomics' average media sentiment score of 0.77 beat Talis Biomedical's score of 0.00 indicating that Bionano Genomics is being referred to more favorably in the media.

Company	Overall Sentiment
Bionano Genomics	Positive
Talis Biomedical	Neutral

Do insiders and institutionals hold more shares of BNGO or TLIS?

11.4% of Bionano Genomics shares are held by institutional investors. Comparatively, 43.8% of Talis Biomedical shares are held by institutional investors. 0.9% of Bionano Genomics shares are held by company insiders. Comparatively, 46.0% of Talis Biomedical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Which has more risk & volatility, BNGO or TLIS?

Bionano Genomics has a beta of 2.06, indicating that its stock price is 106% more volatile than the S&P 500. Comparatively, Talis Biomedical has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500.

Is BNGO or TLIS more profitable?

Talis Biomedical has a net margin of 0.00% compared to Bionano Genomics' net margin of -271.02%. Talis Biomedical's return on equity of -79.74% beat Bionano Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bionano Genomics	-271.02%	-130.31%	-71.18%
Talis Biomedical	N/A	-79.74%	-57.16%

Do analysts prefer BNGO or TLIS?

Bionano Genomics presently has a consensus price target of $7.00, suggesting a potential upside of 130.26%. Given Bionano Genomics' stronger consensus rating and higher probable upside, analysts clearly believe Bionano Genomics is more favorable than Talis Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bionano Genomics	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
Talis Biomedical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Bionano Genomics and Talis Biomedical tied by winning 8 of the 16 factors compared between the two stocks.